Group 1 - The core viewpoint of the article is that卓正医疗 has passed the main board listing hearing and is focusing on the mid-to-high-end medical service market in China, targeting affluent customers [1] -卓正医疗 aims to become the third largest private mid-to-high-end comprehensive medical service provider in China by 2024, with a market share of 2% in this segment and approximately 0.1% in the broader mid-to-high-end market [1] - The private mid-to-high-end medical service market in China is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2020 to 2024, and is expected to continue growing at a CAGR of 14.3% from 2024 to 2029 [1] Group 2 -卓正医疗 has established a network of medical service institutions in several developed cities in China, with plans to operate 19 facilities by October 28, 2025, and has clinics in Singapore and Malaysia [1]

Core Viewpoint -卓正医疗控股有限公司 is strategically focused on the mid-to-high-end medical service market in China, targeting affluent consumers with a preference for personalized healthcare services [1][2] Group 1: Company Overview -卓正医疗 is the third-largest private mid-to-high-end comprehensive medical service provider in China, with a market share of 2.0% based on 2024 revenue [1] -By 2025, the company will operate 19 medical service institutions across China, including 17 clinics and 2 hospitals, and has additional clinics in Singapore and Malaysia [2] -The company employs a family medicine model that integrates both physical and online healthcare services, enhancing patient satisfaction and facilitating cross-specialty referrals [2] Group 2: Market Dynamics -The total revenue of China's private mid-to-high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, representing a compound annual growth rate (CAGR) of 21.9% [2] -Private mid-to-high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in the mid-to-high-end medical service market in China by 2024 [1] Group 3: Financial Performance -卓正医疗's revenue has shown a consistent upward trend, with figures of RMB 473 million, RMB 690 million, and RMB 959 million for the years 2022 to 2024, respectively [3] -The company recorded net losses of RMB 222 million and RMB 353 million in 2022 and 2023, but achieved profits of approximately RMB 80.2 million and RMB 83.2 million in 2024 and the first eight months of 2025 [3] -The company has a team of 387 full-time doctors, with an average of 15 years of experience, and 79% of them previously worked in top-tier hospitals [3]

Core Insights - The article highlights that Zhuozheng Medical is strategically focused on the mid-to-high-end healthcare service market, targeting affluent consumers who prefer personalized medical services. As of 2024, Zhuozheng Medical is the third-largest private mid-to-high-end comprehensive healthcare service provider in China, with a market share of 2.0% [2]. Industry Overview - The mid-to-high-end healthcare service market in China is defined as comprehensive customized services that emphasize patient experience and service quality. This market can be further divided into public and private mid-to-high-end healthcare services. The affluent population is defined as those with an annual disposable income exceeding RMB 200,000 [2]. - By 2024, private mid-to-high-end healthcare institutions are expected to account for approximately 66.5% of the total revenue in the mid-to-high-end healthcare service market in China, which represents about 5.6% of the total revenue in the healthcare service industry [2]. - The total revenue of China's private mid-to-high-end healthcare service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9%. The market is expected to continue growing at a CAGR of 14.3% from 2024 to 2029, reaching RMB 831.4 billion by 2029 [2]. Company Overview - Zhuozheng Medical has established a network covering major economically developed cities in China, including Shenzhen, Guangzhou, Beijing, Chengdu, Suzhou, Changsha, Shanghai, Chongqing, Hangzhou, and Wuhan. As of October 28, 2025, the company operates 19 medical service institutions in China, comprising 17 clinics and 2 hospitals [3]. - The company employs a family medical model that integrates both in-person and online healthcare services, offering a range of specialties including pediatrics, dentistry, ophthalmology, dermatology, ENT, surgery, gynecology, and internal medicine, thereby enhancing patient satisfaction and facilitating cross-specialty referrals [4]. Financial Performance - Zhuozheng Medical's revenue has shown a consistent upward trend, with reported revenues of RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024. For the eight months ending August 31, 2025, the company reported revenue of RMB 696.7 million [4][5]. - The company recorded net losses of RMB 222 million in 2022 and RMB 353 million in 2023. However, it achieved a profit of approximately RMB 80.2 million in 2024 and RMB 83.2 million for the eight months ending August 31, 2025 [4][5].

Core Viewpoint - 卓正医疗控股有限公司 is focusing on the high-end medical service market in China, targeting affluent consumers who prefer personalized healthcare services, and is preparing for its listing on the Hong Kong Stock Exchange [1][4]. Company Overview - 卓正医疗 is the third-largest private high-end comprehensive medical service provider in China, with a market share of 2.0% based on projected revenues for 2024 [4]. - The company operates a network of 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [5]. Market Analysis - The private high-end medical service market in China is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9%. It is expected to continue growing at a CAGR of 14.3% from 2024 to 2029, reaching RMB 831.4 billion by 2029 [4]. - Private high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in the high-end medical service market in China by 2024 [4]. Business Model - 卓正医疗 employs a family healthcare model that integrates both in-person and online medical services, enhancing patient satisfaction and facilitating cross-specialty referrals [6]. - The company has a structured talent development framework to attract and retain qualified medical professionals, with 387 full-time doctors averaging about 15 years of experience [6]. Financial Performance - Revenue figures for 卓正医疗 from 2022 to 2024 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, indicating a consistent upward trend [7]. - The company recorded net losses of RMB 222 million in 2022 and RMB 353 million in 2023, but achieved a profit of approximately RMB 80.2 million in 2024 [6][7].